Mitsubishi UFJ Trust & Banking Corp Lowers Position in United Therapeutics Corporation $UTHR

Mitsubishi UFJ Trust & Banking Corp trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 19.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,038 shares of the biotechnology company’s stock after selling 13,401 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in United Therapeutics were worth $22,653,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in UTHR. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics during the second quarter worth $29,000. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB increased its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Up 0.9%

NASDAQ:UTHR opened at $473.36 on Tuesday. The company has a market cap of $20.38 billion, a P/E ratio of 17.94, a P/E/G ratio of 2.51 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The company’s 50-day moving average price is $487.69 and its 200-day moving average price is $416.98.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the firm earned $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $429.25, for a total value of $9,658,125.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 536,864 shares of company stock worth $255,191,362 over the last quarter. Insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on UTHR shares. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. UBS Group increased their target price on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.